An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Trial Profile

An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2018

At a glance

  • Drugs Domatinostat (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms SENSITIZE
  • Sponsors 4SC
  • Most Recent Events

    • 31 Jul 2018 According to a 4SC media release, first patient in the second dose cohort has been enrolled.
    • 03 Jul 2018 According to a 4SC media release, the Safety Review Committee evaluated the safety data from the first dose cohort and recommended continuation with the second dose cohort. Data from the first two of three cohorts expected in H2 2018 and topline results of the complete study are expected in H1 2019. Full data analysis of the first patient cohort will be published at an upcoming conference.
    • 21 Mar 2018 According to a 4SC media release, this study is expected to complete in H1 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top